Cancer Biology & Genetics Program
The Viviane Tabar Lab
I am a neurosurgeon-scientist and Chair of the Department of Neurosurgery. I have clinical expertise in the surgical management of brain tumors such as complex gliomas, meningiomas, and skull base tumors.
The lab is focused on two major themes: harnessing the potential of human pluripotent stem cells for brain repair and tumor modeling and studying glioma biology with a focus on tumor cell heterogeneity and the microenvironment.
Berlin C, Lange K, Lekaye HC, Hopland K, Phillips S, Piao J, Tabar V. Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment. Neuro Oncol. 2020 April 2; 22(8): 1126-1137PMCID: PMC7594568.
Dincer Z, Piao J, Niu L, Ganat Y, Kriks S, Zimmer B, Shi S, Tabar V, Studer Let al. Specification of functional cranial placode derivatives from human pluripotent stem cells. Cell Rep. 2013;5(5):1387-1402. PMCID: PMC3887225
Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014 Dec 19;346(6216):1529-33. PMCID: PMC4995593
Viviane Tabar, MD
- Physician-scientist Viviane Tabar focuses on stem cells as tools for brain repair and for modeling brain cancer.
- MD, American University of Beirut
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Viviane Tabar discloses the following relationships and financial interests:
American University of Beirut
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.